EP1537236A2 - Amelioration apportee a un procede de synthese d'acides nucleiques - Google Patents

Amelioration apportee a un procede de synthese d'acides nucleiques

Info

Publication number
EP1537236A2
EP1537236A2 EP03750483A EP03750483A EP1537236A2 EP 1537236 A2 EP1537236 A2 EP 1537236A2 EP 03750483 A EP03750483 A EP 03750483A EP 03750483 A EP03750483 A EP 03750483A EP 1537236 A2 EP1537236 A2 EP 1537236A2
Authority
EP
European Patent Office
Prior art keywords
polymerase
rna polymerase
rna
synthesis
ntps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03750483A
Other languages
German (de)
English (en)
Inventor
Guido Krupp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMPTEC GmbH
Original Assignee
ARTUS GESELLSCHAFT fur MOLEKULARBIOLOGISCHE DIAGNOSTIK und ENTWICKLUNG MBH
ARTUS GES fur MOLEKULARBIOLOG
Artus Gesellschaft fur Molekularbiologische Diagnostik und Entwicklung Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARTUS GESELLSCHAFT fur MOLEKULARBIOLOGISCHE DIAGNOSTIK und ENTWICKLUNG MBH, ARTUS GES fur MOLEKULARBIOLOG, Artus Gesellschaft fur Molekularbiologische Diagnostik und Entwicklung Mbh filed Critical ARTUS GESELLSCHAFT fur MOLEKULARBIOLOGISCHE DIAGNOSTIK und ENTWICKLUNG MBH
Publication of EP1537236A2 publication Critical patent/EP1537236A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]

Definitions

  • the present invention relates to improved methods for the synthesis of nucleic acids, in which a polymerase, a nucleic acid which can serve as a template for the polymerase, NTPs and Mn 2+ are incubated under conditions which enable the synthesis of a nucleic acid strand, the conditions being characterized in that are that they have a Mn 2+ / NTP molar ratio of not more than 0.7.
  • the invention relates in particular to methods for the production of RNA, in which a DNA is used as a template and an amplification rate of at least 1000-fold is achieved.
  • the present invention relates to kits which comprise components necessary for carrying out the method according to the invention.
  • nucleic acids in vitro are required for a large number of molecular biological methods, for example for cloning, sequence analysis, in vitro expression, etc. Accordingly, methods have been developed by means of which Nucleic acids can be synthesized in vitro. The processes can generally be distinguished by the reaction product, DNA or RNA.
  • In vitro transcription is a process for the synthesis of RNA, usually starting from a double-stranded DNA template.
  • RNA polymerase and NTPs for an enzymatic reaction in the
  • Mg + is thus an important component of the reaction and is usually added in excess compared to the NTP concentration (Milligan and Uhlenbeck, Methods in Enzymology, Vol. 180 (1989), 51-62; and yatt et al. , Biotechniques, Voll. 11 (1991), 764-769).
  • US Pat. No. 5,256,555 suggests using the nucleotides in the reaction in a concentration of more than 16 mM.
  • the Mg + required for the reaction should be used in a concentration which is not more than 10% above the concentration of the sum of all nucleotides.
  • Inorganic pyrophosphatase should also be present in the reaction mixture.
  • PCR polymerase chain reaction
  • single-stranded primers oligonucleotides with a chain length of usually 12 to 24 nucleotides
  • the primers are extended to a double strand by means of a DNA polymerase and the deoxyribonucleoside triphosphates (dNTPs, namely dATP, dCTP, dGTP, dTTP).
  • dNTPs deoxyribonucleoside triphosphates
  • the double strand is separated into single strands by exposure to heat.
  • the temperature is lowered to such an extent that single-strand primers attach again to the DNA single-strands.
  • the primers are elongated again into a second strand by the DNA polymerase.
  • reaction conditions can be selected in such a way that a double strand is formed from almost every single DNA strand during each reaction run, which is subsequently split back into two single strands, which again serve as a matrix for further strands.
  • a reverse transcription is carried out before this method, in which a DNA single strand (the so-called cDNA) is formed from an RNA by means of an RNA-dependent DNA polymerase, the PCR reaction can also be carried out directly on the multiplication of nucleic acids from a RNA sequence applicable (cf. EP 201 184).
  • DE 101 43 106.6 and DE 102 24 200.3 describe both methods for the amplification of ribonucleic acids, which comprise a combination of individual steps of the PCR reaction and a transcription.
  • the term “molar ratio Mn 2 + / NTP” is used to represent the quotient of the molar concentra- tion ratio of the MMnn ++ iimm ratio to the molar concentration of all NTPs as a number.
  • the conditions for the synthesis of the nucleic acid strand are selected such that the molar ratio of Mn 2+ / NTP is from 0.2 to 0.6, preferably from 0.3 to 0.5.
  • the total concentration of the NTPs is preferably 4 to 24 mM; when using four different NTPs, 1 to 6mM each.
  • Mn + of 0.8 M molar ratio of 0.2 when the NTPs are 4mM
  • 14.4 mM molar ratio of 0.6 when the NTPs are 24mM
  • RNA polymerases in particular of DNA-dependent RNA polymerase, which require a DNA as template which contains a promoter for the synthesis of RNA, are particularly preferred for all embodiments of the invention. It can thus be, for example, a T7 RNA polymerase, a T3 RNA polymerase, or an SP6 RNA polymerase.
  • the RNA polymerase can be an RNA-dependent or a DNA-dependent polymerase. Most of the naturally DNA-dependent RNA polymerases can also recognize RNA as a template if a suitable structure is present (cf. Konarska, MM and Sharp, PA, CellVol. 57 (1989), 423-431; and Konarska, MM and Sharp, PA, 1990, Cell Vol. 63: 609-618).
  • the polymerase and the nucleic acid, which serves as the template, must match.
  • the nucleic acid, which can serve as a template for an RNA polymerase must have, for example, recognition sequences or recognition structures which enable the RNA polymerase to start the synthesis.
  • DNA is preferably used as a template for the RNA polymerase.
  • Corresponding DNA can contain a promoter region which can be recognized by the RNA polymerase and used for the start of the synthesis.
  • the DNA can form a recognition structure that enables the RNA polymerase to initiate the synthesis.
  • Corresponding recognition structures are described, for example, in Krupp (Nucleic Acids Res. Vol. 17 (1989), 3023-3036) and in Kuhn et al. (Nature Vol. 344 (1990), 559-562).
  • the nucleic acid used as a template for the polymerase can be present in a very low concentration.
  • the template can be used, for example, in the form of DNA or mRNA in an amount of at least 0.1 picogram, or 0.2 attomol in a batch of 20 ⁇ l, thus a concentration of at least 10 femtomolar.
  • the reaction mixture contains NTPs, ATP, UTP, CTP and GTP usually being used when using an RNA polymerase. In the case of a transcription customary in the prior art, all of the NTPs mentioned here are used in one reaction mixture. However, it may also be desirable or advantageous to use only one or some of the NTPs.
  • dNTPs can also be used when carrying out the method according to the invention using the RNA or DNA polymerase.
  • This procedure has the particular advantage that the transcript receives all or part of the DNA properties, i.e. it becomes nuclease resistant and provides a better template for RNA polymerase.
  • DATP, dTTP, dCTP and / or dGTP are usually used as dNTPs.
  • NTPs and / or the dNTPs can be present as a modified compound or derivatives.
  • Derivatizations customary in the prior art include the coupling of biotin or a fluorescent marker, which can simplify, for example, the detection of the synthesis products.
  • the reaction time and other reaction conditions can be easily selected by the person skilled in the art depending on the polymerase used and the amplification rate to be achieved.
  • the incubation period can be, for example, from 1 to 24 hours, preferably from 4 to 16 hours.
  • T7 RNA polymerase it makes sense to carry out the reaction in the range from 30 ° C to 45 ° C.
  • the method according to the invention enables a surprising improvement in the amplification rate.
  • the ratio of the amount of synthetically produced nucleic acids to the amount of the template originally present is referred to as the amplification rate.
  • the method according to the invention enables an amplification rate of at least 1000, preferably at least 2000. With optimal reaction conditions, an amplification rate of 2500 was even achieved.
  • the methods according to the invention can be used for a variety of purposes.
  • the improved methods for producing nucleic acids can be used, for example, in the methods described in DE 101 43 106.6 and DE 102 24 200.3 for the amplification of ribonucleic acids.
  • the nucleic acids obtained by means of the method according to the invention can be bound to a chip as probes.
  • the methods can be used for in vitro transcription, for the investigation of interactions with nucleic acid binding factors, as aptamers for the specific binding of molecules, as ribozmye, etc.
  • kits for the synthesis of nucleic acids which comprise, in one or more containers, a polymerase, NTPs, dNTPs and / or their derivatives (for example biotinylated or fluorescence-linked NTPs or dNTPs) and Mn + .
  • the polymerase is preferably a DNA-dependent RNA polymerase which, for the synthesis of RNA, requires a DNA as a template which contains a promoter.
  • the RNA polymerase is the T7 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase.
  • Corresponding kits preferably also contain instructions for performing one of the methods according to the invention.
  • Corresponding instructions or manuals describe exactly the amount in which the individual components of the reaction have to be mixed with one another in order to obtain optimum synthesis performance.
  • the transcription performance of the RNA polymerase was determined as a function of different concentrations of Mn 2 ' + and Mg + .
  • Inhibitor 40 U T7 RNA polymerase, 4 mM NTPs (each; gives a total of 16 mM) and Mn 2+ or Mg 2+ in a concentration of 4 mM to 10 mM and pipetted together and incubated for 16 hours.
  • the aim of this example was to determine the optimal NTP concentration depending on the Mn / NTP ratio.
  • Example 2 For this purpose, series of experimental approaches for in vitro transcription as in Example 1 were created.
  • the concentration of the individual NTPs was from 2 mM to 10 mM and the concentration of the MnCl 2 was from 2.4 mM to 24 mM. This results in Mn / NTP ratios of 0.3 to 0.6.
  • the amount of transcript (in ng) obtained from the transcription was determined by ethidium bromide staining of the gel and a series of RNA dilutions as the standard in the gel.
  • the amplification rate of the in vitro transcription was determined as a function of time.
  • an in vitro transcription reaction was first prepared as described in Example 1, using 4.8 mM MnCl 2 and 4 mM NTP (total 16 mM) (corresponds to a ratio of 0.3).

Abstract

La présente invention concerne un procédé de synthèse d'acides nucléiques. Ce procédé consiste à mettre en incubation dans certaines conditions une polymérase, un acide nucléique pouvant servir de matrice à la polymérase, des nucléotides triphosphate (NTP) et Mn<2+>, qui permettent la synthèse d'un brin d'acide nucléique. Ce procédé est caractérisé en ce que les conditions comprennent un rapport molaire de Mn<2+>/NTP inférieur ou égal à 0,7.
EP03750483A 2002-09-04 2003-09-02 Amelioration apportee a un procede de synthese d'acides nucleiques Withdrawn EP1537236A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10240868 2002-09-04
DE10240868A DE10240868A1 (de) 2002-09-04 2002-09-04 Verbesserte Verfahren zur Synthese von Nukleinsäuren
PCT/EP2003/009756 WO2004022574A2 (fr) 2002-09-04 2003-09-02 Amelioration apportee a un procede de synthese d'acides nucleiques

Publications (1)

Publication Number Publication Date
EP1537236A2 true EP1537236A2 (fr) 2005-06-08

Family

ID=31724332

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03750483A Withdrawn EP1537236A2 (fr) 2002-09-04 2003-09-02 Amelioration apportee a un procede de synthese d'acides nucleiques

Country Status (5)

Country Link
US (1) US20060172299A1 (fr)
EP (1) EP1537236A2 (fr)
AU (1) AU2003270143A1 (fr)
DE (1) DE10240868A1 (fr)
WO (1) WO2004022574A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10837039B2 (en) * 2014-06-10 2020-11-17 Curevac Real Estate Gmbh Methods and means for enhancing RNA production
WO2016180430A1 (fr) 2015-05-08 2016-11-17 Curevac Ag Procédé de production d'arn
WO2016193206A1 (fr) 2015-05-29 2016-12-08 Curevac Ag Procédé de production et de purification d'arn, comprenant au moins une étape de filtration à flux tangentiel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5407800A (en) * 1986-08-22 1995-04-18 Hoffmann-La Roche Inc. Reverse transcription with Thermus thermophilus polymerase
US5561058A (en) * 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
US6027913A (en) * 1988-01-28 2000-02-22 Sommer; Steven S. Nucleic acid amplification with direct sequencing
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5545522A (en) * 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
IL100040A (en) * 1990-11-13 1995-12-31 Siska Diagnostics Inc Amplification of nucleic acids by replicating a self-sustaining enzymatic sequence
EP0519053B1 (fr) * 1990-12-31 1997-10-29 Promega Corporation Amplification d'acide nucleique par l'activite d'arn polymerase adn-dependante d'arn replicases
US5256555A (en) * 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
WO1993018176A1 (fr) * 1992-03-11 1993-09-16 Dana-Farber Cancer Institute Procedes de clonage d'arn messager
US5262311A (en) * 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
US5514545A (en) * 1992-06-11 1996-05-07 Trustees Of The University Of Pennsylvania Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics
US5780273A (en) * 1993-04-09 1998-07-14 Amoco Corporation Insertion elements and amplifiable nucleic acids
DK0632134T3 (da) * 1993-07-01 2001-12-03 Hoffmann La Roche Reagenser og fremgangsmåder til koblet revers transkription ved høj temperatur og polymerase-kædereaktioner
US5459037A (en) * 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
EP1251182A3 (fr) * 1993-12-01 2002-11-27 Toyo Boseki Kabushiki Kaisha Procédé d'amplification et de détection d'une séquence nucléotidique au moyen d'enzymes thermostables
JPH1028585A (ja) * 1996-07-16 1998-02-03 Toyobo Co Ltd 耐熱性リボヌクレアーゼｈを用いる核酸増幅法
US5871929A (en) * 1996-07-23 1999-02-16 Barnes; Wayne M. Suppression of pyrophosphorolysis in DNA sequencing and in other applications involving DNA replication
US5958688A (en) * 1997-04-28 1999-09-28 The Trustees Of The University Of Pennsylvania Characterization of mRNA patterns in neurites and single cells for medical diagnosis and therapeutics
US5932451A (en) * 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
US6132997A (en) * 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
AU2001250858A1 (en) * 2000-03-17 2001-10-03 Gene Logic, Inc. Methods of preparing amplified nucleic acid molecules
US6379932B1 (en) * 2000-07-17 2002-04-30 Incyte Genomics, Inc. Single primer PCR amplification of RNA
DE10143106C1 (de) * 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004022574A2 *

Also Published As

Publication number Publication date
DE10240868A1 (de) 2004-03-18
AU2003270143A8 (en) 2004-03-29
AU2003270143A1 (en) 2004-03-29
US20060172299A1 (en) 2006-08-03
WO2004022574A2 (fr) 2004-03-18
WO2004022574A3 (fr) 2004-04-22

Similar Documents

Publication Publication Date Title
DE69333891T2 (de) Verfahren zur Nukleinsäurenamplifizierung, Zusammensetzung und Kit
EP1889925B1 (fr) Introduction d&#39;éléments de séquence dans des acides nucléiques
DE69829328T2 (de) Strangverdrängungsamplifikation von RNA
DE69334092T2 (de) Nachweis von Mycobacterium tuberculosis durch Vervielfältigung von Nukleinsäuresequenzen
AT502823B1 (de) Polynukleotid-amplifikation
DE19915141C2 (de) Detektion von Nucleinsäure-Amplifikaten
DE10150121A1 (de) Echtzeitdetektion von DNA-Amplifikationsprodukten
EP0705905A2 (fr) Procédé pour la détection sensible d&#39;acides nucléiques
DE60209617T2 (de) Quantitative Multiplex-PCR mit grossem Dynamikbereich
EP1509623B1 (fr) Amplification d&#39;acides ribonucléiques
EP0545010A1 (fr) Procédé pour l&#39;amplification spécifique de séquences d&#39;acides nucléiques
EP0874914B1 (fr) Procede d&#39;amplification d&#39;acide nucleique
EP0437774B1 (fr) Procédé pour la préparation d&#39;acides nucléiques modifiés
EP0534345A2 (fr) Procédé de préparation spécifique d&#39;acide ribonucléique
EP1537236A2 (fr) Amelioration apportee a un procede de synthese d&#39;acides nucleiques
EP2467498A1 (fr) Procédé de détection d&#39;acides nucléiques cibles
EP0645449B1 (fr) Méthode pour le clonage spécifique d&#39;acides nucléiques
EP1072686A2 (fr) Procédé d&#39;enrichissement des cADN, dépendant du 5&#39;-cap
WO1994029443A1 (fr) Analyse de sequences d&#39;arn par pcr
DE10143106C1 (de) Vermehrung von Ribonukleinsäuren
DE69914942T2 (de) Kennzeichnung einer substanz mittels eines reportergens und sequenzen, die für die in vitro expression des reportergens notwendig sind
WO2001049880A2 (fr) Amorce, notamment pour processus de synthese d&#39;acide nucleique et amplifications d&#39;acide nucleique
DE10209071A1 (de) Standardisierte Polynukleotidsysteme, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0598332A2 (fr) Procédé simple de multiplication d&#39;acides nucléiques
EP0713913B1 (fr) Système de transcription amélioré

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050404

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMPTEC GMBH

17Q First examination report despatched

Effective date: 20060324

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071026